Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669043 · ClinicalTrials.gov registry record · NA
Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT02669043 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 8 participants.
The verdict
NCT02669043, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hours in many patients with "treatment-resistant" depression, has been associated with superior efficacy in those individuals with anxious compared with non-anxious depression. In order to understand this unique effect more fully, the current protocol is aimed at further delineating biomarkers of ketamine's effects among individuals with treatment-resistant anxious depression compared to those with nonanxious depression.
Interventions
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669043
The ClinicalTrials.gov registry entry for NCT02669043 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketamine is the first listed.
NCT02669043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669043 about?
NCT02669043 is a clinical study titled "Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects". Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hou...
What is the current status of trial NCT02669043?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2016-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02669043?
The interventions under investigation include: Ketamine (DRUG).
Who is sponsoring clinical trial NCT02669043?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.